European Union approves use Emphanx vaccine against monkey pox
Al-anbat - Hamad Alhmaisat
The European Commission has agreed to expand use of the
Danish company's Bavarian Nordic vaccine to combat monkey pox.
According to Euronews, the company said in a statement, on Monday
that "the approval of the monkey pox vaccine is an example of good cooperation
between the company and European regulators, while such a decision usually
takes 6 to 9 months.”
The commission's green light is valid in all EU member
states, as well as in Iceland, Liechtenstein and Norway.
The promotion of the Emphanex vaccine as Genius in the
United States, where it has been approved to combat monkey pox since 2019,
makes it the only licensed vaccine for the disease.
Also, the European Medicines Authority (EMA) gave its
approval Friday for the use of the Emphanex vaccine against monkey pox, which
has been approved since 2013 in the European Union against human smallpox.